Marcus Schindler
Chief Tech/Sci/R&D Officer chez NOVO NORDISK A/S
Profil
Marcus Schindler est Chief Scientific Officer et Executive VP-Research chez Novo Nordisk A. Il est titulaire d'un doctorat de l'université de Cambridge.
Postes actifs de Marcus Schindler
| Sociétés | Poste | Début |
|---|---|---|
| NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 01/03/2021 |
Anciens postes connus de Marcus Schindler
| Sociétés | Poste | Fin |
|---|---|---|
| INNATE PHARMA | Director/Board Member | 28/05/2021 |
| The Oxford | Chief Tech/Sci/R&D Officer | 29/02/2008 |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Chief Tech/Sci/R&D Officer | - |
AstraZeneca A/S /Denmark/
 AstraZeneca A/S /Denmark/ Pharmaceuticals: MajorHealth Technology AstraZeneca A/S sells and distributes pharmaceutical products to the health sector. It specializes within therapy areas of the gastrointestinal diseases, respiratory diseases, cardiovascular diseases, neuroscience, and oncology. The company was founded in 1943 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Formation de Marcus Schindler
| University of Cambridge | Doctorate Degree |
| University of Gottingen | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| INNATE PHARMA | Health Technology |
| Entreprise privées | 3 |
|---|---|
| The Oxford | Consumer Services |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
AstraZeneca A/S /Denmark/
AstraZeneca A/S /Denmark/ Pharmaceuticals: MajorHealth Technology AstraZeneca A/S sells and distributes pharmaceutical products to the health sector. It specializes within therapy areas of the gastrointestinal diseases, respiratory diseases, cardiovascular diseases, neuroscience, and oncology. The company was founded in 1943 and is headquartered in Copenhagen, Denmark. | Health Technology |
